Hirve Siddhivinayak, Lambach Philipp, Paget John, Vandemaele Katelijn, Fitzner Julia, Zhang Wenqing
Global Influenza Program, World Health Organization, Geneva, Switzerland.
Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland.
Influenza Other Respir Viruses. 2016 Jul;10(4):254-67. doi: 10.1111/irv.12374. Epub 2016 May 26.
The evidence needed for tropical countries to take informed decisions on influenza vaccination is scarce. This article reviews policy, availability, use and effectiveness of seasonal influenza vaccine in tropical and subtropical countries.
Global health databases were searched in three thematic areas - policy, availability and protective benefits in the context of human seasonal influenza vaccine in the tropics and subtropics. We excluded studies on monovalent pandemic influenza vaccine, vaccine safety, immunogenicity and uptake, and disease burden.
Seventy-four countries in the tropics and subtropics representing 60% of the world's population did not have a national vaccination policy against seasonal influenza. Thirty-eight countries used the Northern Hemisphere and 21 countries the Southern Hemisphere formulation. Forty-six countries targeted children and 57 targeted the elderly; though, the age cut-offs varied. Influenza vaccine supply increased twofold in recent years. However, coverage remained lower than five per 1000 population. Vaccine protection against laboratory-confirmed influenza in the tropics ranged from 0% to 42% in the elderly, 20-77% in children and 50-59% in healthy adults. Vaccinating pregnant women against seasonal influenza prevented laboratory-confirmed influenza in both mothers (50%) and their infants <6 months (49-63%).
Guidelines on vaccine composition, priority risk groups and vaccine availability varied widely. The evidence on vaccine protection was scarce. Countries in the tropics and subtropics need to strengthen and expand their evidence-base required for making informed decisions on influenza vaccine introduction and expansion, and how much benefit to expect.
热带国家做出有关流感疫苗接种的明智决策所需的证据稀缺。本文综述了热带和亚热带国家季节性流感疫苗的政策、可及性、使用情况及有效性。
在三个主题领域检索全球卫生数据库——热带和亚热带地区人类季节性流感疫苗的政策、可及性及保护效益。我们排除了关于单价大流行性流感疫苗、疫苗安全性、免疫原性及接种率以及疾病负担的研究。
热带和亚热带地区的74个国家(占世界人口的60%)没有针对季节性流感的国家疫苗接种政策。38个国家使用北半球配方,21个国家使用南半球配方。46个国家将儿童作为目标人群,57个国家将老年人作为目标人群;不过,年龄界限各不相同。近年来流感疫苗供应增加了两倍。然而,覆盖率仍低于每千人口5例。在热带地区,疫苗对实验室确诊流感的保护率在老年人中为0%至42%,在儿童中为20%至77%,在健康成年人中为50%至59%。为孕妇接种季节性流感疫苗可预防母亲(50%)及其6个月以下婴儿(49%至63%)的实验室确诊流感。
关于疫苗成分、优先风险群体和疫苗可及性的指南差异很大。关于疫苗保护的证据稀缺。热带和亚热带国家需要加强和扩大其证据基础,以便就引入和扩大流感疫苗接种以及预期的效益做出明智决策。